ILMN Q1 Deep Dive: Clinical Sequencing Fuels Growth as NovaSeq X Demand Surges

Genomics company Illumina (NASDAQ:ILMN) reported Q1 CY2026 results exceeding the market’s revenue expectations, with sales up 4.8% year on year to $1.09 billion. The company’s full-year revenue guidance of $4.57 billion at the midpoint came in 0.8% above analysts’ estimates. Its non-GAAP profit of $1.15 per share was 9% above analysts’ consensus estimates.

Is now the time to buy ILMN? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Illumina’s first quarter reflected consistent execution across its clinical and instrument businesses. Management highlighted strong demand in clinical sequencing, which now represents more than 65% of sequencing consumables revenue, and robust uptake of the NovaSeq X platform, with over 80 placements in the quarter. CEO Jacob Thaysen credited disciplined operational performance and expansion of sequencing-based diagnostics for driving revenue and margin growth, noting, “Our focus on delivering for our customers and shareholders is fueling the sustained success that positions us for continued growth well into the future.”

Looking ahead, Illumina’s full-year guidance is underpinned by continued momentum in its clinical segment and an expanding installed base of NovaSeq X instruments. Management expects further growth in consumables revenue as newly placed instruments ramp up utilization, while ongoing investments in innovation—such as the upcoming spatial transcriptomics launch and new high-throughput flow cells—are designed to strengthen the product portfolio. CFO Ankur Dhingra emphasized, “Our solid Q1 performance and rapidly growing clinical installed base provide a good setup going into the second half of the year, and as these Xs come online, they will add to the consumables revenue stream.”

Key Insights from Management’s Remarks

Management attributed the quarter’s results to broad-based clinical demand, higher NovaSeq X placements, and early benefits from recent product introductions, while inflationary pressures were largely offset by operational discipline.

• Clinical sequencing momentum: Illumina saw strong adoption of sequencing-based diagnostics, with clinical representing over 65% of sequencing consumables revenue. Demand for comprehensive genomic profiling and whole-genome sequencing continued to accelerate, particularly as customers adopted more data-intensive applications.
• NovaSeq X platform expansion: The company placed more than 80 NovaSeq X instruments, about 20 more than in the same quarter last year, with placements split between clinical and research markets. Management emphasized that clinical placements were mostly additive, driving incremental revenue rather than simply replacing older systems.
• Product innovation drives engagement: New offerings like TruePath—streamlining whole-genome sequencing by removing traditional library prep—and imminent launches in spatial transcriptomics are generating customer enthusiasm. Early access users reported success with challenging samples, and Illumina expects these innovations to support future consumables growth.
• Operational discipline amid inflation: Despite higher component and freight costs, margins rose as Illumina managed expenses and benefitted from scale. CFO Ankur Dhingra noted that mitigating actions were underway to offset near-term inflationary pressures, supporting margin expansion plans for the remainder of the year.
• SomaLogic integration on track: The recently closed acquisition of SomaLogic performed in line with expectations, primarily contributing to the microarrays segment, and management reiterated confidence in its revenue and profitability impact.

Drivers of Future Performance

Illumina’s outlook centers on sustained clinical demand, ongoing innovation in high-throughput sequencing, and careful navigation of research market headwinds.

• Clinical segment fuels growth: Management expects continued double-digit growth in clinical sequencing, supported by broader reimbursement and adoption of advanced genomic applications such as rare disease diagnostics and oncology. As more NovaSeq X instruments are deployed, consumables revenue is set to benefit in the second half of the year.
• Innovation pipeline to expand opportunities: Planned launches—including new high-throughput flow cells and a spatial transcriptomics solution—are designed to enhance the NovaSeq X platform’s capabilities and address a wider range of customer needs. These additions should help maintain Illumina’s competitive position as rivals introduce lower-cost genome sequencing options.
• Research funding and competitive risks: While clinical markets remain robust, management highlighted ongoing caution in research and academic markets due to funding uncertainties. The company acknowledged that competitive pressures and pricing dynamics could pose headwinds but believes its product roadmap and installed base will help mitigate these risks.

Catalysts in Upcoming Quarters

In upcoming quarters, the StockStory team will watch (1) whether clinical sequencing maintains its double-digit growth pace as new NovaSeq X instruments are installed, (2) successful launch and adoption of spatial transcriptomics and advanced flow cells, and (3) signs of stabilization or recovery in research and applied markets as funding dynamics evolve. Additionally, ongoing integration of SomaLogic and the ability to offset inflationary pressures will be key performance indicators.

Illumina currently trades at $128.00, in line with $126.74 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it’s free).

Stocks That Trumped Tariffs

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week - FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.